Hubálek, Frantisek http://orcid.org/0000-0003-3983-7900
Refsgaard, Hanne H. F.
Gram-Nielsen, Sanne http://orcid.org/0000-0001-9576-9397
Madsen, Peter http://orcid.org/0000-0003-0398-7309
Nishimura, Erica http://orcid.org/0000-0001-5741-3648
Münzel, Martin http://orcid.org/0000-0002-4504-8281
Brand, Christian Lehn
Stidsen, Carsten Enggaard http://orcid.org/0000-0002-6636-3600
Claussen, Christian Hove
Wulff, Erik Max http://orcid.org/0000-0002-8149-3067
Pridal, Lone
Ribel, Ulla
Kildegaard, Jonas
Porsgaard, Trine
Johansson, Eva http://orcid.org/0000-0001-9330-5169
Steensgaard, Dorte Bjerre
Hovgaard, Lars
Glendorf, Tine
Hansen, Bo Falck
Jensen, Maja Kirkegaard
Nielsen, Peter Kresten
Ludvigsen, Svend
Rugh, Susanne
Garibay, Patrick W.
Moore, Mary Courtney
Cherrington, Alan D. http://orcid.org/0000-0001-8927-2560
Kjeldsen, Thomas http://orcid.org/0000-0003-0094-9286
Article History
Received: 13 December 2019
Accepted: 1 July 2020
First Online: 27 July 2020
Change Date: 20 August 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-020-18106-3
Competing interests
: All authors except M.C.M. and A.D.C. are present or past employees of Novo Nordisk and hold equity in the company. M.C.M. and A.D.C. received financial support from Novo Nordisk. Insulin analogues and formulations described in this article are covered by Novo Nordisk’s patents and patent applications. A.D.C. reports grants, personal fees, and other from Metavention, Zafgen, and Abvance; grants and/or personal fees from Thetis Pharmaceuticals, Boston Scientific, Novo Nordisk, vTv Therapeutics, Merck, Eli Lilly, and Galvani Bioelectronics; personal fees from California Institute for Biomedical Research (Calibr) and MedImmune; personal fees and other from Fractyl, Biocon and Sensulin Labs.